WO2004072027A3 - Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique - Google Patents

Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique Download PDF

Info

Publication number
WO2004072027A3
WO2004072027A3 PCT/FR2004/000260 FR2004000260W WO2004072027A3 WO 2004072027 A3 WO2004072027 A3 WO 2004072027A3 FR 2004000260 W FR2004000260 W FR 2004000260W WO 2004072027 A3 WO2004072027 A3 WO 2004072027A3
Authority
WO
WIPO (PCT)
Prior art keywords
specifically
quadruplex dna
cancer agent
specific anti
chemical derivatives
Prior art date
Application number
PCT/FR2004/000260
Other languages
English (en)
Other versions
WO2004072027A2 (fr
Inventor
Augustin Hittinger
Thomas Caulfield
Patrick Mailliet
Herve Bouchard
Eliane Mandine
Jean-Louis Mergny
Lionel Guittat
Jean-Francois Riou
Dennis Gomez
Chafke Belmokhtar
Original Assignee
Aventis Pharma Sa
Centre Nat Rech Scient
Museum Nat D Histoire Naturell
Inst Curie
Commissariat Energie Atomique
Univ Reims Champagne Ardenne
Augustin Hittinger
Thomas Caulfield
Patrick Mailliet
Herve Bouchard
Eliane Mandine
Jean-Louis Mergny
Lionel Guittat
Jean-Francois Riou
Dennis Gomez
Chafke Belmokhtar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Centre Nat Rech Scient, Museum Nat D Histoire Naturell, Inst Curie, Commissariat Energie Atomique, Univ Reims Champagne Ardenne, Augustin Hittinger, Thomas Caulfield, Patrick Mailliet, Herve Bouchard, Eliane Mandine, Jean-Louis Mergny, Lionel Guittat, Jean-Francois Riou, Dennis Gomez, Chafke Belmokhtar filed Critical Aventis Pharma Sa
Priority to JP2006502131A priority Critical patent/JP2006518726A/ja
Priority to CA002514105A priority patent/CA2514105A1/fr
Priority to AU2004210753A priority patent/AU2004210753A1/en
Priority to EP04708378A priority patent/EP1603898A2/fr
Priority to MXPA05007648A priority patent/MXPA05007648A/es
Priority to BRPI0407320-7A priority patent/BRPI0407320A/pt
Publication of WO2004072027A2 publication Critical patent/WO2004072027A2/fr
Publication of WO2004072027A3 publication Critical patent/WO2004072027A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La présente invention est relative à la thérapie du cancer et concerne de nouveaux agents anticancéreux ayant un mécanisme d'action bien particulier. Elle concerne aussi de nouveaux composés chimiques ainsi que leur application thérapeutique chez l'homme. La présente invention décrit la préparation de diamides hétérocycliques de formule générale (IB) suivante, comme ligants hautement spécifiques d’AND en G-quadruplexe et leur utilisation comme inhibiteurs de télomérase : (IB) Cycle aromatique azoté possédant un atome d’azote sous forme quaternaire - (NR3)p - CO- répartiteur - (CO)m - (NR’3)q -X- cycle aromatique ou non aromatique.
PCT/FR2004/000260 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique WO2004072027A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2006502131A JP2006518726A (ja) 2003-02-07 2004-02-05 Ｇ四重鎖ｄｎａ構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用
CA002514105A CA2514105A1 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
AU2004210753A AU2004210753A1 (en) 2003-02-07 2004-02-05 Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent
EP04708378A EP1603898A2 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d adn en g-quadruplexe et leur application comme agent anticancereux specifique
MXPA05007648A MXPA05007648A (es) 2003-02-07 2004-02-05 Derivados quimicos que se unen de manera muy especifica a las estructuras de adn en g - cuadruplex y su aplicacion como agente anticanceroso especifico.
BRPI0407320-7A BRPI0407320A (pt) 2003-02-07 2004-02-05 derivados quìmicos que se ligam de maneira muito especìfica às estruturas de dna em g-quadrúples e sua aplicação como agente anticanceroso especìfico

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301478A FR2850970B1 (fr) 2003-02-07 2003-02-07 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
FR03/01478 2003-02-07

Publications (2)

Publication Number Publication Date
WO2004072027A2 WO2004072027A2 (fr) 2004-08-26
WO2004072027A3 true WO2004072027A3 (fr) 2004-09-23

Family

ID=32731875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/000260 WO2004072027A2 (fr) 2003-02-07 2004-02-05 Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique

Country Status (8)

Country Link
EP (1) EP1603898A2 (fr)
JP (1) JP2006518726A (fr)
AU (1) AU2004210753A1 (fr)
BR (1) BRPI0407320A (fr)
CA (1) CA2514105A1 (fr)
FR (1) FR2850970B1 (fr)
MX (1) MXPA05007648A (fr)
WO (1) WO2004072027A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
US20110059070A1 (en) * 2006-09-14 2011-03-10 Ramot At Tel Aviv University Ltd. Combination therapy for tumoral desease treatment
GB0706932D0 (en) * 2007-04-10 2007-05-16 Univ London Pharmacy Ureylene derivatives
WO2009040819A2 (fr) 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. Régulation négative de la mortaline par de l'arnsi
JP4410844B1 (ja) 2008-05-27 2010-02-03 パナソニック株式会社 Ｇ−ｑｕａｄｒｕｐｌｅｘ検出方法、Ｇ−ｑｕａｄｒｕｐｌｅｘ形成ＤＮＡ検出方法およびテロメラーゼ活性測定方法
JP4510929B1 (ja) 2009-04-09 2010-07-28 パナソニック株式会社 テロメラーゼ反応阻害方法およびそれに用いられるテロメラーゼ反応阻害剤
CN108066340B (zh) * 2016-11-10 2020-10-27 中国科学院化学研究所 药物组合物
CN108066341B (zh) * 2016-11-10 2020-10-30 中国科学院化学研究所 化合物在制备抗癌药物中的用途
WO2018211148A1 (fr) * 2017-05-19 2018-11-22 Universite De Bretagne Occidentale Dérivés de bisquinolium pour la prévention ou le traitement de cancers liés au veb
AU2019326768A1 (en) * 2018-08-24 2021-03-18 Agricultural University Of Athens (Aua) 2,6-bis(((1H-benzo[d]imidazol-2-yl)thio)methyl)pyridine and N2,N6-dibenzylpyridine-2,6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040218A1 (fr) * 1999-11-29 2001-06-07 Aventis Pharma S.A. Derives arylamines et leur application comme agent antitelomerase
WO2002055515A1 (fr) * 2001-01-09 2002-07-18 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002068408A1 (fr) * 2001-02-23 2002-09-06 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002076975A1 (fr) * 2001-03-23 2002-10-03 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002096903A2 (fr) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040218A1 (fr) * 1999-11-29 2001-06-07 Aventis Pharma S.A. Derives arylamines et leur application comme agent antitelomerase
WO2002055515A1 (fr) * 2001-01-09 2002-07-18 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002068408A1 (fr) * 2001-02-23 2002-09-06 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002076975A1 (fr) * 2001-03-23 2002-10-03 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2002096903A2 (fr) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATWELL G J ET AL: "Potential antitumor agents. V. Bisquaternary salts", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 10, no. 4, 1967, pages 706 - 713, XP002258190, ISSN: 0022-2623 *
ATWELL G J ET AL: "Potential antitumor agents. VI. Bisquaternary salts", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 11, no. 2, 1968, pages 295 - 300, XP002258189, ISSN: 0022-2623 *
CAIN B F ET AL: "POTENTIAL ANTITUMOUR AGENTS. X. BISQUATERNARY SALTS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 12, no. 2, March 1969 (1969-03-01), pages 199 - 206, XP001074169, ISSN: 0022-2623 *
KITTLER L ET AL: "Sequence specific modulation of DNA restriction enzyme cleavage by minor groove binders", BIOLOGICAL CHEMISTRY, XX, XX, vol. 379, no. 4/5, April 1998 (1998-04-01), pages 519 - 525, XP009019122, ISSN: 1431-6730 *
WILLIAM A DENNY ET AL: "Potential Antitumor Agents. 29. Quantitative Structure-Activity Relationships for the Antileukemic Bisquaternary Ammonium Heterocycles", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 22, no. 2, February 1979 (1979-02-01), pages 134 - 150, XP002139936, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
CA2514105A1 (fr) 2004-08-26
FR2850970A1 (fr) 2004-08-13
WO2004072027A2 (fr) 2004-08-26
AU2004210753A1 (en) 2004-08-26
FR2850970B1 (fr) 2006-07-07
EP1603898A2 (fr) 2005-12-14
MXPA05007648A (es) 2006-12-15
BRPI0407320A (pt) 2006-02-21
JP2006518726A (ja) 2006-08-17

Similar Documents

Publication Publication Date Title
BG106526A (en) Therapeutic quinazoline derivatives
PL358281A1 (en) Novel compounds
WO2003004472A8 (fr) Nouveaux composes
WO2002036562A3 (fr) 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6
WO2002008190A3 (fr) Nouveaux derives d'heteroaryle et leur utilisation en tant que medicaments
DK1326613T4 (da) Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering
WO2004072027A3 (fr) Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
WO2002051837A3 (fr) Composes heterocyclylindazole et azaindazole utilises en tant que ligands 5-hydroxytryptamine-6
GB0003154D0 (en) Novel compounds
EP1610751A4 (fr) Compositions therapeutiques conjuguees agent/ligand, leur methodes de synthese et leur utilisation
WO2003082853A8 (fr) Nouveaux composes
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
CA2414095A1 (fr) Nouveaux composes
NO20063787L (no) Terapeutiske preparater
IL149402A0 (en) Arylamine derivatives and their use as anti-telomerase agent
NO20070570L (no) Forbindelser.
WO2002051832A3 (fr) Composes heterocyclylalkylindole ou azaindole comme ligands 5-hydroxytryptamine-6
WO2006035157A3 (fr) Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques
TW200509933A (en) Therapeutic agents
WO2002014281A8 (fr) Inhibiteurs de p38
IL157653A0 (en) Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity
WO2001081332A3 (fr) Composes de 2-fluorobenzenesulfonyle utilises pour le traitement d'inflammations
WO2003015780A3 (fr) Isoxazolopyridinones
WO2005097755A3 (fr) Derives d'imidazol
WO2005102997A8 (fr) Maleimides 3,4-disubstitues utilises en tant qu'agents de degradation vasculaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/007648

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004708378

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2514105

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 169876

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004210753

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006502131

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004210753

Country of ref document: AU

Date of ref document: 20040205

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004210753

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004708378

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0407320

Country of ref document: BR